Show simple item record

dc.contributor.authorvan Ewijk, C E
dc.contributor.authorSmit, C
dc.contributor.authorBavalia, R
dc.contributor.authorAinslie, K
dc.contributor.authorVollaard, A
dc.contributor.authorvan Rijckevorsel, G
dc.contributor.authorHahné, S J M
dc.date.accessioned2023-10-25T08:27:17Z
dc.date.available2023-10-25T08:27:17Z
dc.date.issued2023-10-12
dc.identifier.pmid37838481
dc.identifier.doi10.1016/j.vaccine.2023.10.013
dc.identifier.urihttp://hdl.handle.net/10029/627019
dc.language.isoenen_US
dc.rightsCopyright © 2023 Elsevier Ltd. All rights reserved.
dc.subjectEvaluationen_US
dc.subjectMpoxen_US
dc.subjectPrevention measureen_US
dc.subjectThird-generation smallpox vaccineen_US
dc.subjectVaccination programmeen_US
dc.titleAcceptance and timeliness of post-exposure vaccination against mpox in high-risk contacts, Amsterdam, the Netherlands, May-July 2022.en_US
dc.typeArticleen_US
dc.identifier.eissn1873-2518
dc.identifier.journalVaccine 2023; 41(47):6952-6959en_US
dc.source.journaltitleVaccine
dc.source.countryNetherlands


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record